Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048529 | 0.76 | KMT2A (0.47) | ALDH1A1LMNAHPGDGABRA1GABRB2 | |
| SCHEMBL19889908 | 0.75 | CLEC4M (0.48) | ALDH1A1LMNAGABRA1GABRB2MEN1 | |
| SCHEMBL9921649 | 0.75 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNAGALR2MITF | |
| SCHEMBL9912472 | 0.72 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNAGALR2MITF | |
| SCHEMBL3212436 | 0.71 | MEN1 (0.47) | ALDH1A1SMN1; SMN2LMNAGALR2MITF | |
| SCHEMBL3221048 | 0.70 | MEN1 (0.46) | ALDH1A1SMN1; SMN2LMNAGALR2MITF | |
| SCHEMBL18131166 | 0.70 | MAPT (0.45) | ALDH1A1SMN1; SMN2LMNAGALR2MITF | |
| SCHEMBL1465652 | 0.70 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2LMNAGALR2MITF | |
| SCHEMBL27601395 | 0.70 | CA12 (0.48) | ALDH1A1SMN1; SMN2LMNAGALR2MITF | |
| SCHEMBL9979815 | 0.69 | AR (0.64) | SMN1; SMN2MEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ALDH1A1 1507/4885SMN1; SMN2 4199/4885LMNA 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.